The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,346K data for 622K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

24 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery of a Highly Selective Tankyrase Inhibitor Displaying Growth Inhibition Effects against a Diverse Range of Tumor Derived Cell Lines.EBI
Glaxosmithkline
Highly Potent and Isoform Selective Dual Site Binding Tankyrase/Wnt Signaling Inhibitors That Increase Cellular Glucose Uptake and Have Antiproliferative Activity.EBI
University Of Bath
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.EBI
Health & Science University
Development and structural analysis of adenosine site binding tankyrase inhibitors.EBI
University Of Oulu
Selective inhibition of PARP10 using a chemical genetics strategy.EBI
Oregon Health & Science University
Discovery of potent and selective nonplanar tankyrase inhibiting nicotinamide mimics.EBI
University Of Oulu
Tankyrase 1 Inhibitors with Drug-like Properties Identified by Screening a DNA-Encoded Chemical Library.EBI
Philochem
Towards small molecule inhibitors of mono-ADP-ribosyltransferases.EBI
Karolinska Institutet
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-EBI
Astrazeneca
Medicinal Chemistry Perspective on Targeting Mono-ADP-Ribosylating PARPs with Small Molecules.EBI
University Of Perugia
Rational design, synthesis and biological evaluation of dual PARP-1/2 and TNKS1/2 inhibitors for cancer therapy.EBI
Nanjing University
Potent 2,3-dihydrophthalazine-1,4-dione derivatives as dual inhibitors for mono-ADP-ribosyltransferases PARP10 and PARP15.EBI
University Of Perugia
Analogs of TIQ-A as inhibitors of human mono-ADP-ribosylating PARPs.EBI
University Of Oulu
Development of a 1,2,4-Triazole-Based Lead Tankyrase Inhibitor: Part II.EBI
Symeres
Integrating DNA-encoded chemical libraries with virtual combinatorial library screening: Optimizing a PARP10 inhibitor.EBI
Mcdaniel College
Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development.EBI
TBA
Preclinical Lead Optimization of a 1,2,4-Triazole Based Tankyrase Inhibitor.EBI
University Of Oslo
Discovery of Novel Spiroindoline Derivatives as Selective Tankyrase Inhibitors.EBI
Riken
Design and Discovery of an Orally Efficacious Spiroindolinone-Based Tankyrase Inhibitor for the Treatment of Colon Cancer.EBI
Japanese Foundation For Cancer Research
Discovery and Optimization of 2-Arylquinazolin-4-ones into a Potent and Selective Tankyrase Inhibitor Modulating Wnt Pathway Activity.EBI
Merck Healthcare
Rational Design of Cell-Active Inhibitors of PARP10.EBI
Oregon Health And Science University
4-(Phenoxy) and 4-(benzyloxy)benzamides as potent and selective inhibitors of mono-ADP-ribosyltransferase PARP10/ARTD10.EBI
University Of Oulu
Design, synthesis and evaluation of potent and selective inhibitors of mono-(ADP-ribosyl)transferases PARP10 and PARP14.EBI
Mcdaniel College
Discovery of a Novel Series of Tankyrase Inhibitors by a Hybridization Approach.EBI
Leibniz-Forschungsinstitut F�R Molekulare Pharmakologie (Fmp)